Free Trial
ASX:PAB

Patrys (PAB) Stock Price, News & Analysis

Patrys logo

About Patrys Stock (ASX:PAB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
250,000 shs
Average Volume
N/A
Market Capitalization
$5.14 million
P/E Ratio
N/A
Dividend Yield
8.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Receive PAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

PAB Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Patrys Limited AGM Resolutions Successfully Passed
Patrys Limited Shifts Focus to Promising PAT-DX3 Development
See More Headlines

PAB Stock Analysis - Frequently Asked Questions

Patrys Limited (ASX:PAB) posted its quarterly earnings results on Wednesday, February, 20th. The company reported $0.00 EPS for the quarter. Patrys had a negative trailing twelve-month return on equity of 83.38% and a negative net margin of 253.85%.

Company Calendar

Last Earnings
2/20/2019
Today
5/27/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:PAB
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.54 million
Net Margins
-253.85%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.39 million
Price / Cash Flow
2.40
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,060,000,000
Free Float
N/A
Market Cap
$5.14 million
Optionable
Not Optionable
Beta
0.42
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (ASX:PAB) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners